Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up

Esmatjes, Enric; Maseras, Miquel; Gállego, Marta; Coves, M J; Conget, Ignacio

doi:10.1016/0168-8227(89)90017-x

Cited by 7 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, triflusal has been shown to be an effective inhibitor of platelet aggregation in diabetic patients [10], to reduce the evolution of background diabetic retinopathy [11], and to prevent aortocoronary vein-graft occlusion [12].…”

mentioning

confidence: 99%

Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers

Cruz

Villalobos

García

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

The ex vivo effect of triflusal and acetylsalicylic acid (ASA) on platelet interaction with the subendothelium using the Baumgartner perfusion system (wall shear rate 350 s-1) was assessed in blood from 10 healthy volunteers who given a 15-day course of triflusal 600 mg per day and ASA 400 mg per day in a cross-over trial. The percentage of platelets on the subendothelium showed a decrease of 62% in samples from subjects on ASA and a decrease of 93% in those from subjects on triflusal (P < 0.005). The percentage of the subendothelial surface covered by platelets was reduced by 23.3% after treatment with ASA, mainly due to inhibition of aggregates (75.2%), and by 29.9% after treatment with triflusal, mainly due to inhibition of aggregates (89.6%) and of adhesion (25%). The subendothelial surface covered by activated platelets (adhesions and thrombi) showed 32.5% inhibition after treatment with triflusal and 11.6% after treatment with ASA (P < 0.043 vs. triflusal). In the in vitro experiments, 10 mumol.l-1 triflusal did not modify the percentage of the subendothelium covered by platelets. HTB 1 mmol.l-1 inhibited adhesion (26%) and aggregates (18%). We conclude that HTB participates in the ex vivo effects of triflusal on the platelet-subendothelium interaction.

show abstract

mentioning

confidence: 99%

Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers

Cruz

Villalobos

García

et al. 1995

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…In an open pilot study with triflusal involving 17 patients with type 1 diabetes mellitus and background retinopathy [186], 9 patients took 900 mg/day triflusal and 8 took no antiaggregant. After two years of follow-up, there were no differences between the triflusal and the control groups in visual acuity or computed parameters of the visual field.…”

Section: B) Small Noncontrolled Studiesmentioning

confidence: 99%

Pharmacological approach to diabetic retinopathy

Cruz

González-Correa

Guerrero

et al. 2004

Diabetes Metabolism Res

View full text Add to dashboard Cite

Diabetic retinopathy is the most frequent cause of legal blindness in the population of 30-to-70-year olds. Whether retinopathy appears or not depends mainly on the duration of the disease and the degree of metabolic control the patient maintains. High blood glucose values lead to important changes in cellular metabolism and the main effects of these alterations are endothelial dysfunction that sets in motion the morphological process of diabetic retinopathy. The biochemical lesions caused by prolonged hyperglycemia can be positively influenced, but usually not normalized, pharmacologically with some groups of drugs, which are now under development. This makes tight control of glycemia a key measure in preventing the onset or progression of diabetic retinopathy, together with an effective program of ophthalmologic detection and follow-up in patients with diabetes. Regarding the role of endothelial dysfunction, antiplatelet drugs have been shown to slow some aspects of the evolution of diabetic retinopathy in its initial stages, mainly a lower degree of microaneurysms. However, a new approach to controlling endothelial dysfunction shows promise, mainly through the vascular endothelial growth factor (VEGF) inhibitors. These agents may prove to be especially useful in the treatment of proliferative diabetic retinopathy. Other encouraging results have been obtained in studies of antioxidant drugs and inhibitors of the formation of advanced glycation end products. Once retinal lesions appear, preventive measures need to be redoubled, with special attention to controlling glycemia; however, it is also necessary to resort to laser photocoagulation. This intervention aims to eliminate areas of ischemia and to diminish the formation of retinal exudates. If this measure fails or if vitreous hemorrhage appears, the only remaining therapeutic measure is vitrectomy.

show abstract

The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus

Cruz

Moreno

Mérida

et al. 1996

Thrombosis Research

View full text Add to dashboard Cite

Effect of treatment with an inhibitor of platelet aggregation on the evolution of background retinopathy: 2 years of follow-up

Cited by 7 publications

References 23 publications

Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers

Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers

Pharmacological approach to diabetic retinopathy

The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus

Contact Info

Product

Resources

About